Multicenter Trial of Cryotherapy for Retinopathy of Prematurity

Indirect Diode Laser in the Treatment of Retinopathy of Prematurity

“…Literature shows that lower GA and BW are associated with poorer outcomes of ROP [6]. These observations could not be verified in our series in which statistical tests proved no significant difference in terms of outcome according to GA and BW.…”

Indirect Diode Laser in the Treatment of Retinopathy of Prematurity

“…Literature shows that lower GA and BW are associated with poorer outcomes of ROP [6]. These observations could not be verified in our series in which statistical tests proved no significant difference in terms of outcome according to GA and BW.…”

Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity

“…However, ablative treatment was not found to be effective enough to prevent some aggressive ROP cases progressing to retinal detachment [2,20]. In recent years, studies showed higher rates of favorable outcomes in ROP after IVB treatment as compared to laser ablation, especially in zone I and posterior zone II cases [5,21,22].…”

Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity

“…No standard guidelines for the treatment of ROP existed before the multicenter trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) [2,3]. Subsequently, the Laser ROP Study group and other studies found that laser photocoagulation (LPC) has been used for peripheral retinal ablation with at least equal success and is now the preferred method of ablation [4,5].…”

“…In comparison with other forms of treatment, the efficacy of intravitreal aflibercept monotherapy was nearly the same or higher than LPC with 87.5-92% [6,10] and better than cryotherapy (40%) [2,3]. This could be explained by the role of aflibercept to block VEGF, which is already produced and is present in the vitreous body, while LPC prevents any further production of VEGF in addition to the inflammation induced with cryotherapy.…”

“…The recurrence rate in our study was 7.7% which was comparable with that of the BEAT-ROP group [10], where bevacizumab injection had a recurrence rate of 6% in combined retinal zones I and II compared with a 26% recurrence rate in laser treatment. Data from the CRYO-ROP trial [2,3] and the ETROP trial [6] and BEAT-ROP group [10] suggested that recurrence of ROP generally occurs before 55 weeks postmenstrual age. …”

Indirect Diode Laser in the Treatment of Retinopathy of Prematurity

“…Literature shows that lower GA and BW are associated with poorer outcomes of ROP [6]. These observations could not be verified in our series in which statistical tests proved no significant difference in terms of outcome according to GA and BW.…”

Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity

“…However, ablative treatment was not found to be effective enough to prevent some aggressive ROP cases progressing to retinal detachment [2,20]. In recent years, studies showed higher rates of favorable outcomes in ROP after IVB treatment as compared to laser ablation, especially in zone I and posterior zone II cases [5,21,22].…”

Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity

“…No standard guidelines for the treatment of ROP existed before the multicenter trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) [2,3]. Subsequently, the Laser ROP Study group and other studies found that laser photocoagulation (LPC) has been used for peripheral retinal ablation with at least equal success and is now the preferred method of ablation [4,5].…”

“…In comparison with other forms of treatment, the efficacy of intravitreal aflibercept monotherapy was nearly the same or higher than LPC with 87.5-92% [6,10] and better than cryotherapy (40%) [2,3]. This could be explained by the role of aflibercept to block VEGF, which is already produced and is present in the vitreous body, while LPC prevents any further production of VEGF in addition to the inflammation induced with cryotherapy.…”

“…The recurrence rate in our study was 7.7% which was comparable with that of the BEAT-ROP group [10], where bevacizumab injection had a recurrence rate of 6% in combined retinal zones I and II compared with a 26% recurrence rate in laser treatment. Data from the CRYO-ROP trial [2,3] and the ETROP trial [6] and BEAT-ROP group [10] suggested that recurrence of ROP generally occurs before 55 weeks postmenstrual age. …”

Indirect Diode Laser in the Treatment of Retinopathy of Prematurity

“…Literature shows that lower GA and BW are associated with poorer outcomes of ROP [6]. These observations could not be verified in our series in which statistical tests proved no significant difference in terms of outcome according to GA and BW.…”

Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity

“…However, ablative treatment was not found to be effective enough to prevent some aggressive ROP cases progressing to retinal detachment [2,20]. In recent years, studies showed higher rates of favorable outcomes in ROP after IVB treatment as compared to laser ablation, especially in zone I and posterior zone II cases [5,21,22].…”

Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity

“…No standard guidelines for the treatment of ROP existed before the multicenter trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) [2,3]. Subsequently, the Laser ROP Study group and other studies found that laser photocoagulation (LPC) has been used for peripheral retinal ablation with at least equal success and is now the preferred method of ablation [4,5].…”

“…In comparison with other forms of treatment, the efficacy of intravitreal aflibercept monotherapy was nearly the same or higher than LPC with 87.5-92% [6,10] and better than cryotherapy (40%) [2,3]. This could be explained by the role of aflibercept to block VEGF, which is already produced and is present in the vitreous body, while LPC prevents any further production of VEGF in addition to the inflammation induced with cryotherapy.…”

“…The recurrence rate in our study was 7.7% which was comparable with that of the BEAT-ROP group [10], where bevacizumab injection had a recurrence rate of 6% in combined retinal zones I and II compared with a 26% recurrence rate in laser treatment. Data from the CRYO-ROP trial [2,3] and the ETROP trial [6] and BEAT-ROP group [10] suggested that recurrence of ROP generally occurs before 55 weeks postmenstrual age. …”